6190 Stock Overview
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
PhoenixBio Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥487.00 |
52 Week High | JP¥628.00 |
52 Week Low | JP¥442.00 |
Beta | 0.46 |
1 Month Change | 2.10% |
3 Month Change | 5.41% |
1 Year Change | -17.74% |
3 Year Change | -20.94% |
5 Year Change | -32.83% |
Change since IPO | -82.91% |
Recent News & Updates
Recent updates
Shareholder Returns
6190 | JP Life Sciences | JP Market | |
---|---|---|---|
7D | 1.5% | 1.0% | 1.0% |
1Y | -17.7% | -29.6% | 38.6% |
Return vs Industry: 6190 exceeded the JP Life Sciences industry which returned -29.6% over the past year.
Return vs Market: 6190 underperformed the JP Market which returned 38.6% over the past year.
Price Volatility
6190 volatility | |
---|---|
6190 Average Weekly Movement | 4.5% |
Life Sciences Industry Average Movement | 6.0% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 6190 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6190's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 65 | Takashi Shimada | https://www.phoenixbio.co.jp |
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations.
PhoenixBio Co., Ltd. Fundamentals Summary
6190 fundamental statistics | |
---|---|
Market cap | JP¥1.97b |
Earnings (TTM) | JP¥114.00m |
Revenue (TTM) | JP¥1.79b |
17.2x
P/E Ratio1.1x
P/S RatioIs 6190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6190 income statement (TTM) | |
---|---|
Revenue | JP¥1.79b |
Cost of Revenue | JP¥582.00m |
Gross Profit | JP¥1.21b |
Other Expenses | JP¥1.10b |
Earnings | JP¥114.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
Earnings per share (EPS) | 28.30 |
Gross Margin | 67.52% |
Net Profit Margin | 6.36% |
Debt/Equity Ratio | 28.2% |
How did 6190 perform over the long term?
See historical performance and comparison